Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma

被引：4
|
作者：
Kim, E. Bridget [1 ]
Harrington, Cynthia [1 ]
Yee, Andrew [1 ]
O'Donnell, Elizabeth [1 ]
Branagan, Andrew [1 ]
Burke, Jill [1 ]
Raje, Noopur [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
daratumumab; real-world evidence; retreatment;
D O I：
10.1016/j.clml.2019.09.435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-109
引用
收藏
页码：E263 / E263
页数：1
相关论文
共 50 条
  • [1] Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Galusic, Davor
    Krecak, Ivan
    Blaslov, Viktor
    Opara, Andela Krstulovic
    Valkovic, Toni
    Kinda, Sandra Basic
    BIOMEDICINES, 2025, 13 (01)
  • [2] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    DRUGS, 2017, 77 (18) : 2013 - 2024
  • [3] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2017, 77 : 2013 - 2024
  • [4] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Luo, Man
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2019, 134 (08) : 668 - 677
  • [5] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2018, 78 : 397 - 397
  • [6] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
    贾亚静
    China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189
  • [7] Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
    Bapatla, Anusha
    Kaul, Arunima
    Dhalla, Paramvijay Singh
    Armenta-Quiroga, Ana S.
    Khalid, Raheela
    Garcia, Jian
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [8] Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients
    Nooka, Ajay K.
    Joseph, Nisha
    Boise, Larry H.
    Gleason, Charise
    Kaufman, Jonathan L.
    Lonial, Sagar
    BLOOD, 2016, 128 (22)
  • [9] Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
    Oostvogels, Rimke
    Jak, Margot
    Raymakers, Reinier
    Mous, Rogier
    Minnema, Monique C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 60 - 67
  • [10] EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Oostvogels, R.
    Jak, M.
    Minnema, M. C.
    HAEMATOLOGICA, 2018, 103 : 33 - 33
12345